Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate

Abstract Metronomic chemotherapy is an anticancer strategy which uses conventional cytotoxic drugs administered at very low dose in close intervals. We have designed a phase ii trial to investigate the safety and antitumor activity of the newest metronomic chemo-hormonal-therapy with daily cyclophosphamide and twice daily megestrol acetate (MCM regimen) in patients with metastatic pretreated breast cancer. Twenty-nine pretreated post-menopausal patients with multiple metastatic sites were enrolled. Four patients had a triple negative status, nineteen a positive hormonal ER and PGR status, and three ERB-B2 over-expression. Patients received treatment with cyclophosphamide (50 mg/daily day 1-21/q28) and fractionated megestrol acetate (80 mg twice a day). The overall objective response rate was 31.0%, disease control rate 41.3%, mean time to tumor progression 7.4 months (CI 95%, 3.8-10.88, range 1-48 months) and mean overall survival 13.4 months (CI 95%, 7.24-17.18, range 1-53 months). The MCM regimen was active and well tolerated.

[1]  P. Conte,et al.  Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. , 2009, The oncologist.

[2]  E. Alba,et al.  Maintenance treatment in metastatic breast cancer , 2008, Expert review of anticancer therapy.

[3]  G. Francini,et al.  A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. , 2006, Oncology reports.

[4]  V. Michalaki,et al.  Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Letrozole or Anastrozole. A Phase II Trial Conducted by the Hellenic Group of Oncology (HELGO) , 2006, Tumori.

[5]  R. Kaufmann,et al.  Metronomic low‐dose chemotherapy as antiangiogenic therapeutic strategy for cancer , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[6]  M. Sabatino,et al.  Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens , 2002, Cancer Chemotherapy and Pharmacology.

[7]  S. Haga,et al.  Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer , 2002, Breast cancer.

[8]  G. Gasparini,et al.  Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.

[9]  G. Hortobagyi,et al.  Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. , 2001, The oncologist.

[10]  M. A. Seguí,et al.  Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. , 1998, American journal of clinical oncology.

[11]  S. Martino,et al.  Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Cocconi,et al.  Cisplatin and VP16 in Metastatic Breast Carcinoma as a Third-Line Chemotherapy: A Randomized Study Comparing Low versus High Doses of Cisplatin , 1995, Tumori.

[13]  G. Brufman,et al.  Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. , 1994, Oncology.

[14]  G. Francini,et al.  Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. , 2007, Urology.

[15]  Z. Ortiz,et al.  Megestrol acetate for the treatment of anorexia-cachexia syndrome. , 2005, The Cochrane database of systematic reviews.

[16]  A. Goldhirsch,et al.  Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.